SVRA Savara Inc.
-
Savara Beat Consensus Estimates
Monday, November 9, 2026 · 12:00 AM ET
Savara (SVRA) reported a loss of $0.17 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $0.18 per share. The company beat consensus estimates by 5.56%.
Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.17)
Earnings Whisper®
—
Consensus Estimate
($0.18)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—